What to expect in the NEKTAR THERAPEUTICS interview process

Based on publicly available sources, Nektar Therapeutics is a San Francisco-headquartered biopharmaceutical company founded in 1990 that specializes in therapeutics built on its advanced polymer conjugate chemistry technology platform. Operating with a distributed workforce across 11 countries—including the United States, India, Canada, the United Kingdom, and the United Arab Emirates—the company employs around 231 people and maintains an annual revenue of approximately $55.2M to over $100M.

Employee sentiment data reveals a mixed picture of day-to-day realities inside the organization. On one hand, internal wellbeing surveys reflect an "Above average" overall work wellbeing score of 73, driven by high scores in day-to-day happiness and purpose, alongside manageable work stress. Conversely, employee satisfaction regarding the way things are at work registers as "Below average."

Leadership and human resources metrics highlight notable friction points. CEO Howard W. Robin receives a low approval rating (around 21% to 51% depending on the metric scale), and employee ratings place company leadership in the bottom 30% in San Francisco, scoring a C-. The human resources department—led by executives including Dorian Rinella, Bethany Bankowski, and Jennifer Lambrecht—is also tied to an overall culture score of C. While immigration data shows historical H-1B visa support with certified petitions, job seekers evaluating the company should weigh positive indicators around meaningful scientific work and purpose against clear internal employee dissatisfaction with executive leadership and company culture.